论文部分内容阅读
目的研究用胃癌干细胞(GSC)冻融抗原制备GSC-树突状细胞(DC)共培养细胞因子诱导的杀伤细胞(CIK)联合化疗对晚期胃癌患者的临床疗效。方法选取72例晚期胃癌患者分为联合治疗组(40例,DC-CIK生物治疗联合化疗)和对照组(32例,常规化疗)。观察两组患者治疗前后T细胞亚群变化、临床疗效。用SPSS 13.0对数据进行t检验和χ2检验。结果联合治疗组患者经过GSC-DC-CIK联合化疗方案治疗后,CD3+、CD4+、CD8+和CD56+T淋巴细胞百分比均较治疗前及对照组治疗后显著升高,差异均有统计学意义(P<0.05)。对照组治疗有效率为43.75%,肿瘤控制率为53.13%;联合治疗组治疗有效率为57.50%,肿瘤控制率为80.00%。两组治疗有效率的差异无统计学意义(χ2=1.346,P>0.05),肿瘤控制率的差异有统计学意义(χ2=5.906,P<0.05)。结论采用GSC-DC-CIK联合化疗方法能够提高免疫细胞功能、提高疗效,具有较强的临床推广价值。
Objective To study the clinical efficacy of gastric cancer stem cells (GSC) freeze-thaw antigen preparation GSC-dendritic cells (DC) co-cultured with cytokine-induced killer cells (CIK) combined with chemotherapy in patients with advanced gastric cancer. Methods Seventy-two patients with advanced gastric cancer were divided into combined treatment group (40 cases, DC-CIK combined with chemotherapy) and control group (32 cases, conventional chemotherapy). The changes of T cell subsets in two groups before and after treatment were observed and the clinical effects were observed. Data were subjected to t-test and χ2 test using SPSS 13.0. Results The percentage of CD3 +, CD4 +, CD8 + and CD56 + T lymphocytes in the combined treatment group after treatment with GSC-DC-CIK combined with chemotherapy was significantly higher than that before treatment and in the control group (P <0.05). The effective rate of the control group was 43.75% and the tumor control rate was 53.13%. The effective rate of the combination therapy group was 57.50% and the tumor control rate was 80.00%. There was no significant difference between the two groups in the treatment efficiency (χ2 = 1.346, P> 0.05). The difference in tumor control rate was statistically significant (χ2 = 5.906, P <0.05). Conclusion The combination of GSC-DC-CIK and chemotherapy can improve immune cell function and improve the curative effect, and has strong clinical value.